The EU already has an agreement in place with the two companies, and Denmark has now decided to join the union’s acquisition programme for the vaccines, health minister Magnus Heunicke confirmed in a Twitter post.
The European Commission signed the agreement with Pfizer and BioNTech on November 11th, securing the purchase of 200 million doses of vaccines produced by the two companies.
Around two million of these have now been reserved for people in Denmark, according to Heunicke.
“Last week, the EU entered another agreement for the purchase of vaccines. This time with Pfizer,” the minister tweeted.
“Denmark has now decided to join this agreement, which ensures the vaccination of two million persons if the vaccine is safe and effective and is approved by the authorities,” he added.
Vaccinenyhed: I sidste uge indgik EU endnu en forhåndsaftale om indkøb af vacciner. Denne gang med Pfizer. Danmark har nu besluttet at tiltræde aftalen, der sikrer vaccination af ca. 2 mio. personer, hvis vaccinen er sikker og effektiv og godkendes af myndighederne.#covid19dk
— Magnus Heunicke (@Heunicke) November 19, 2020
The EU already has vaccine purchase agreements in place with a number of companies, including CureVac, AstraZeneca, Sanofi/GSK and Johnson & Johnson, as well as Pfizer and BioNTech.
The two latter companies’ vaccines are nearing approval, with good results from phase 3 trials, the final stage of clinical testing before approval.
43,000 people in total took part in the two companies’ trials. Pfizer is an American pharmaceutical company, while BioNTech is a German bio technology firm.
Additionally, the EU is in talks over a deal with Moderna, which has also announced good results from phase 3 trials of its developmental Covid-19 vaccine.
EU countries agreed in June this year to enable the EU Commission to make advance agreements with up to six different vaccine developers, with a budget of up to 2.7 billion euros.